Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Cerebral Palsy
Interventions: Smart Ankle-Foot Orthosis, 5-Azacitidine, Placebo; Device · Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 8 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions: PZ-128, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia

Conditions: Pain Management
Interventions: MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Chronic Low-back Pain (cLBP), Myofacial Pain
Interventions: Dry Needling, Sham Dry Needling, NUN Biomarker; Device · Other
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 20 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Fragile X Syndrome
Interventions: Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Blood Loss, Surgical
Interventions: Trasylol (Aprotinin, BAYA0128), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Erchonia® FX-635™, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Alcohol Risk Behaviors
Interventions: Intermittent Theta Burst Stimulation, Continuous Theta Burst Stimulation, Sham Transcranial Magnetic Stimulation; Device
Lead sponsor: Michael J. Wesley, PhD; Other
Eligibility: 21 Years to 29 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pulmonary Artery Hypertension
Interventions: Metformin, Placebo, mHealth Intervention, Usual Care; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Nashvile, Tennessee

Conditions: Stroke, Muscle Spasticity
Interventions: Botox (botulinum toxin); Drug
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Artery Disease
Interventions: Beetroot juice, Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Charlottesville, Virginia

Conditions: Type 2 Diabetes
Interventions: Placebo Attention Control, Supervised Exercise Training; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Myocardial Infarction
Interventions: Percutaneous Coronary Intervention (PCI), RO4905417, placebo; Procedure · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years to 74 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: Back Pain
Interventions: cognitive behavioral therapy, desipramine hydrochloride, benztropine mesylate 0.125 mg daily; Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Resilience, HIV-1-infection, Stress, Psychological
Interventions: RISE+, Stress Reduction Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Hypogonadism
Interventions: testosterone, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Orthodontic Appliance, Pain, Transcutaneous Electric Nerve Stimulation, Orthodontic Appliance Complication
Interventions: Active TENS Device, Intervention 2: Placebo/Sham Device; Device
Lead sponsor: University of the Pacific; Other
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Orthostatic Intolerance, Parkinson's Disease
Interventions: Midodrine; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 22 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Beverly Hills, California • Chapel Hill, North Carolina

Conditions: Colorectal Cancer
Interventions: Aspirin, Placebo for Aspirin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Metoprolol succinate, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years to 84 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 21 more

Conditions: End Stage Renal Disease, Thrombosis
Interventions: AB002 Dose 1, AB002 Dose 2, placebo; Drug
Lead sponsor: Aronora, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

Treatment Validation for Myofascial Pain

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

Mitigating the Disinhibiting Effects of Alcohol With Transcranial Magnetic Stimulation

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle

BEETroot Juice to Reverse Functional Impairment in PAD

Barriers to Physical Activity in People With Type 2 Diabetes

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Efficacy of Antidepressants in Chronic Back Pain

Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Testosterone Replacement in Men With Diabetes and Obesity

The Effect of Intraoral Transcutaneous Electrical Nerve Stimulation in Orthodontics Pain

Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

ASPirin Intervention for the REDuction of Colorectal Cancer Risk

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis